Latest media releases
UBS Investment Bank Strengthens Healthcare Banking Team by Hiring Four Managing Directors
UBS Investment Bank announced today that it has hired four senior investment bankers within the firm's Healthcare Banking group. Denis Fabre, Steven L. Fisch, M.D., Les Franks and Holly Sheffield will join the firm's Investment Banking Department (IBD) as Managing Directors. Fisch, Franks and Sheffield will report to M. Robert DiGia, Global Head of Healthcare banking, and will be based in New York City. Fabre will be based in London and report to Doug McCutcheon, Head of Healthcare for Europe, Middle East and Africa (EMEA) and Asia-Pacific (APAC).
"Denis, Steven, Les and Holly are each outstanding in their fields, with proven credibility advising top-tier clients and delivering strategic solutions," said DiGia. "We are thrilled they will be joining UBS and are confident they will continue to strengthen and advance our coverage of the sector, offering unique, strategic advisory and financing solutions for clients."
Fabre will be responsible for the medical technology and services segments of Healthcare in EMEA. He was most recently a Managing Director on the Healthcare Team at Deutsche Bank. Prior to Deutsche Bank, he worked at Lehman Brothers and Bear Stearns. Denis has an MBA from The Wharton School at the University of Pennsylvania, and a degree in Business Administration and Finance from HEC, Ecole des Hautes Etudes Commerciales, France.
Fisch will have responsibility for the Firm's life sciences coverage efforts. Fisch has worked for the past 16 years advising clients, including time spent at Credit Suisse as Co-Head of Life Sciences and at Citi as Co-Head of US Healthcare. He most recently worked as an independent consultant advising healthcare companies and has also worked for the Adaptive Design Association, a nonprofit that makes customized equipment for children with disabilities. Fisch holds an MD from the College of Physicians and Surgeons at Columbia University and was a resident in Internal Medicine at New York-Presbyterian Hospital. He holds a BA from the University of Pennsylvania.
Franks will oversee sectors within Services including distribution, pharmaceutical services and healthcare information technology. He will join UBS from Thomas Weisel Partners where he was a Managing Director on their healthcare team. He previously spent eight years at Banc of America Securities, most recently as a Managing Director. Earlier in his career, Franks worked at UBS in the Healthcare group. Franks holds an MBA from the Columbia Business School and a BS from University of Georgia, Athens.
Sheffield will be responsible for banking coverage for all subsectors of medical technology. She will join UBS after 13 years at Credit Suisse where she was most recently a Managing Director in Healthcare Banking in San Francisco and New York. Sheffield holds an MBA from Columbia Business School and a BA from Cornell University.
Rick Leaman, Global Head of IBD, added, "Healthcare is an important and key sector to UBS. By bringing on board talented and highly sought after bankers like Denis, Steven, Les and Holly, it demonstrates UBS's commitment to growing this integral part of the business. I believe we will quickly see an impact from their addition to the Healthcare Banking group."
UBS's Global Healthcare Group is one of the largest healthcare investment banking groups in the industry with over 50 bankers across the US, Europe, Asia, Australia and Latin America. The group's 16 senior coverage officers provide coverage across the healthcare services, pharmaceuticals, specialty pharmaceuticals, medical technology and biotechnology sectors.
Over the past several months, UBS's Global Healthcare Group has worked on numerous high-profile transactions in capital markets and M&A advisory with an aggregate value of more than $10 billion. Notable transactions include: Joint Global Coordinator and Joint Bookrunning Manager on Sinopharm's $1.1 billion Initial Public Offering, the largest ever healthcare IPO in Asia; Joint Bookrunning Manager on Emdeon's $422 million Initial Public Offering, the largest Healthcare IT IPO in 10 years; Lead Bookrunning Manager on Cumberland Pharmaceuticals' $85 million Initial Public Offering, the first U.S. biopharmaceutical IPO in the last 22 months; Exclusive Financial Advisor to Concateno Plc on its $240 million sale to Inverness Medical Innovations, Inc.; Joint Bookrunning Manager on Merck & Co's $4.25 billion 4-Tranche Bond Offering, representing the first debt transaction UBS has led for Merck.
Headquartered in Zurich and Basel, Switzerland, UBS is one of the world's leading financial firms. It serves a discerning, international client base with its wealth management, investment banking and asset management businesses. In Switzerland, UBS is the market leader in retail and commercial banking.
UBS is present in all major financial centers worldwide. It has offices in over 50 countries, with about 38% of its employees working in the Americas, 34% in Switzerland, 15% in the rest of Europe and 13% in Asia Pacific. UBS employs more than 75,000 people around the world. Its shares are listed on the SIX Swiss Exchange, the New York Stock Exchange (NYSE) and the Tokyo Stock Exchange (TSE).